Alessandra Gennari MD PhD

The @asco and @esmo presidents-elect @SABCSSanAntonio @curijoey @ASCOPres

@myESMO @ProfKHerrmann Join us 😍 radioligands will go to next level in cancer care

Are you ready for radioligand therapy? Join the next #ESMOOnAir webinar part of the Therapeutic Landscapes series: - Science, clinical trials & system readiness for RLT - Live expert Q&A 🔗 ow.ly/b4Es50XnBxm #Oncology #Radiotheranostics #CancerCare #RLT #MedicalEducation

Oggi e come sempre, tutti #INSIEME a @delmastro_lucia per @AIOMtweet! ♥️ @OncoAlert

Insieme alla cura dei pazienti e alla ricerca, la formazione dei giovani oncologi è una delle componenti più belle del nostro lavoro. Quando il risultato sono eccellenze come Matteo Lambertini, si viene ripagati di tutto l’impegno e le energie investiti!

Absolutely AMAZING discussion by Ana Garrido-Castro on ASCENT-03 and TROPiON-Breast02!!! @DFCI_BreastOnc #ESMO25 @OncoAlert

What’s interesting is the control arm in post-Monarch (CDK46 inhibitor prior treatment) was fulvestrant alone w/ ~50% mutPIK3CA and had mPFS 5.3 months. Sometimes it does help us compare how different populations of post-CDK4/6 inhibitor patients can be. #ESMO25

#ESMO25: Positive phase III #ClinicalTrial data with T-DXd in high-risk, HER2+ #EarlyBreastCancer suggest that a paradigm change in the treatment of these patients may be imminent. Read more in the #ESMODailyReporter 📌ow.ly/FvVq50XeuyE #BreastCancer #ADC @E_de_Azambuja

Interesting news re: abemaciclib in MonarchE trial. At 5 years, the OS data in @JCO_ASCO was NS with HR 0.9.

La preservazione della fertilità è parte essenziale della cura in oncologia. Grazie all’@ass_coscioni per aver dato spazio a questo tema, che riguarda il futuro di donne e uomini colpiti da tumore. Parlare, informare, accompagnare: è anche questo prendersi cura.

Onorata di intervenire a #ESCCardioOnco2025 La collaborazione tra diversi specialisti è un esempio concreto di quanto la multidisciplinarietà sia cruciale nella cura del cancro @escardio @AIOMtweet #cardiooncology #collaborazione #oncologia #cardiologia #INSIEME

@AIOMtweet @AiomFondazione @AIRC_it @_sirm @ComunediGenova @tourvespucci @delmastro_lucia @matteolambe @CarloGenova5 @Poggio_Fra @DSoldatoMD @boutrosand @UniGenova @LucreziaBarc @beatricerampol @Dr_LucaLucente @silviapuglisi95 @AnnaliceGandini @Lucarecco

Da oggi al 14 con @AIOMtweet @AiomFondazione @AIRC_it @_sirm saremo al Porto Antico del @ComunediGenova per parlare di #prevenzione in oncologia in occasione dell'arrivo del @tourvespucci @delmastro_lucia @matteolambe @CarloGenova5 @Poggio_Fra @DSoldatoMD @boutrosand @UniGenova

RT @PTarantinoMD: SERENA6 presentation by Nick Turner. What it shows: that a switch to camizestrant/CDKi vs continuing AI/CDKi can keep pts…

@stolaney1 @DFCI_BreastOnc wow congrats Jennifer well deserved 😍

A big congratulations to Dr. Jennifer Ligibel on her promotion to Professor at Harvard Medical School-- very well deserved! @DFCI_BreastOnc

NEWS FROM INDUSTRY Source AstraZeneca astrazeneca.com/media-centre/p… The Phase III DESTINY-Breast09 trial marks a significant advancement in HER2-positive metastatic #BreastCancer treatment, showing that trastuzumab deruxtecan combined with pertuzumab delivers a statistically significant and clinically meaningful improvement in PFS 🆚 the current 1st-line standard regimen of taxane, trastuzumab, and pertuzumab (THP). This is the first trial in over a decade to demonstrate superior efficacy across a broad HER2-positive metastatic population in the 1st-line setting. While OS data remain immature, early trends favor the Enhertu combination. Ping OncoAlert Breast #Cancer Faculty @matteolambe @aftimosp @E_de_Azambuja @NicoleKuderer @FAndreMD @prat_aleix @DrSGraff @jesusanampa @StoverLab @curijoey @ErikaHamilton9 @double_whammied @stage4kelly @coffeemommy @itsnot_pink @maryam_lustberg @IBCResearch @kevinpunie @nicolobattisti @raalbany @hoperugo @teamoncology @stolaney1 @LoiSher @SirohiBhawna @chemobrainfog @jamecancerdoc @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @paspears88 @MammaMiaMagazin @itrisabel #OncoAlertAF @nataliagandur @acampsmalea @BiagioRicciutMD @yekeduz_emre @HHorinouchi @FadiHaddad_MD @Dr_Ivanoncologo @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK

📣ESMO Living Guidelines on Metastatic Breast Cancer: 👉Just updated with the latest recommendations and algorithms in an interactive format. 🔗ow.ly/loX750VBoN6 #ClinicalPracticeGuideline

T-DXd approval finally expanded also in Europe to patients with HR+/HER2-0 (ultralow) disease or chemo-naive pts. Appealing post-ET option for patients with aggressive disease course. Congrats @curijoey for leading the DB06 trial that backed this approval! astrazeneca.com/media-centre/p…

Important analyses. Thinking about treatment selection by actual prognosis/risk, and not by study eligibility, is a long standing approach in breast cancer. As was discussed @SG_BCC St Gallen last month, it should be applied to decision making in adjuvant CDK46i selection, too.

Our Collaborators at @high5md are here in San Antonio bringing you LIVE Reports from #SABCS24 🇺🇸from TOP international Experts🌐in #BreastCancer Find their Coverage here: high5oncology.tv/meeting-covera… Experts include @hoperugo @curijoey @Prof_Nadia_H @ALEDIGNUS12 @stolaney1 and many more